{"product_id":"agenusbio-business-model-canvas","title":"Agenus Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgenus's Cancer Fight: Business Model Unveiled!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic core of Agenus's groundbreaking approach to cancer immunotherapy. This comprehensive Business Model Canvas dissects how they innovate, partner, and deliver value to patients and stakeholders. Discover the intricate details of their revenue streams and cost structure to understand their competitive edge.\u003c\/p\u003e\n\u003cp\u003eReady to gain a competitive advantage? Our full Business Model Canvas for Agenus provides a detailed, section-by-section breakdown of their operations, from key resources to customer relationships. Download it now to accelerate your own strategic planning and market analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharma Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgenus actively pursues strategic collaborations with major pharmaceutical firms. These alliances are vital for co-development, licensing, and eventual commercialization of its promising immuno-oncology assets.\u003c\/p\u003e\n\u003cp\u003eSuch partnerships are instrumental in securing essential funding, accessing specialized expertise, and gaining broader market reach. This accelerates the journey of therapies, like BOT\/BAL, from development to patient access. For instance, Agenus recently partnered with Zydus Lifesciences, highlighting its strategy to leverage external capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CDMO Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgenus's manufacturing strategy hinges on key partnerships, notably its transition of US biologics CMC facilities to a fee-for-service model with Zydus Lifesciences. This strategic move positions Agenus as Zydus's inaugural BioCDMO client, ensuring exclusive manufacturing of BOT\/BAL.\u003c\/p\u003e\n\u003cp\u003eThis partnership provides Agenus with secured long-term manufacturing without the burden of operational risk. Furthermore, it unlocks significant upfront capital and potential milestone payments, bolstering Agenus's financial flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgenus actively cultivates Research and Development Alliances with other biotechnology firms and leading academic institutions. These strategic collaborations are designed to expand the therapeutic applications of Agenus' existing clinical assets and to investigate novel combination strategies. For instance, partnerships aim to tackle immunosuppression within the tumor microenvironment, thereby enhancing the overall efficacy of immunotherapy treatments.\u003c\/p\u003e\n\u003cp\u003eKey R\u0026amp;D alliances include those with Targovax, Oxford BioTherapeutics, and Immunogenesis. These collaborations are crucial for Agenus' strategy to broaden its pipeline and explore synergistic effects of its technologies. In 2024, Agenus continued to leverage these partnerships to accelerate the development of its immuno-oncology candidates, focusing on unmet needs in cancer treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI and Predictive Biomarker Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgenus is forging key partnerships with AI and technology pioneers, including a notable collaboration with Noetik. This alliance focuses on developing sophisticated AI-enabled predictive biomarkers.\u003c\/p\u003e\n\u003cp\u003eThese collaborations leverage advanced computational models and extensive multimodal tumor data. The goal is to pinpoint patients who are most likely to respond positively to immunotherapies such as BOT\/BAL, thereby accelerating the advancement of precision immunotherapy.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAI-driven biomarker development\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePartnerships with tech leaders like Noetik\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUtilizing multimodal tumor data for patient stratification\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAccelerating precision immunotherapy\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty and Milestone Monetization Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgenus actively monetizes its intellectual property through strategic partnerships focused on future royalty and milestone payments. These agreements provide crucial non-dilutive capital to fuel ongoing research and development.\u003c\/p\u003e\n\u003cp\u003eA notable example is the 2020 agreement with Ligand Pharmaceuticals, where Agenus sold a portion of future royalties and milestones from six partnered assets. This included a share of potential royalties from BOT\/BAL sales, demonstrating a clear strategy to unlock value from its pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMonetization Strategy:\u003c\/strong\u003e Agenus partners with entities to sell future royalty streams and milestone payments from its partnered assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLigand Pharmaceuticals Deal:\u003c\/strong\u003e In 2020, Agenus secured funding by divesting a percentage of future royalties and milestones from six partnered assets, including a stake in BOT\/BAL sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapital for Development:\u003c\/strong\u003e This approach provides essential capital to support ongoing clinical trials and the advancement of its innovative cancer therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Biotech Innovation and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgenus's Key Partnerships are multifaceted, encompassing collaborations with major pharmaceutical companies for co-development and commercialization, as seen with its BOT\/BAL assets. These alliances are critical for funding, expertise, and market access, exemplified by the Zydus Lifesciences partnership which also secured Agenus's manufacturing.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Agenus engages in R\u0026amp;D alliances with biotech firms and academic institutions, such as Targovax and Oxford BioTherapeutics, to broaden its pipeline and explore synergistic therapies. The company also partners with technology leaders like Noetik to develop AI-driven predictive biomarkers for precision immunotherapy, leveraging extensive tumor data.\u003c\/p\u003e\n\u003cp\u003eAgenus also monetizes its intellectual property through partnerships, like the 2020 deal with Ligand Pharmaceuticals, to sell future royalties and milestones, generating non-dilutive capital for its ongoing research and development efforts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartner Type\u003c\/th\u003e\n\u003cth\u003eExample Partner\u003c\/th\u003e\n\u003cth\u003ePurpose\u003c\/th\u003e\n\u003cth\u003eKey Benefit\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma Co-development\u003c\/td\u003e\n\u003ctd\u003eZydus Lifesciences\u003c\/td\u003e\n\u003ctd\u003eCo-development, Licensing, Commercialization, Manufacturing\u003c\/td\u003e\n\u003ctd\u003eSecured manufacturing, upfront capital, milestone payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Alliance\u003c\/td\u003e\n\u003ctd\u003eTargovax, Oxford BioTherapeutics\u003c\/td\u003e\n\u003ctd\u003ePipeline expansion, novel combination strategies\u003c\/td\u003e\n\u003ctd\u003eAccelerated development, exploration of synergistic effects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Partnership\u003c\/td\u003e\n\u003ctd\u003eNoetik\u003c\/td\u003e\n\u003ctd\u003eAI-driven biomarker development\u003c\/td\u003e\n\u003ctd\u003ePrecision immunotherapy, patient stratification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Monetization\u003c\/td\u003e\n\u003ctd\u003eLigand Pharmaceuticals\u003c\/td\u003e\n\u003ctd\u003eSale of future royalties and milestones\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive capital for R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA detailed breakdown of Agenus's approach to developing and commercializing immuno-oncology therapies, covering its target patient populations, research and development pipeline, and strategic partnerships.\u003c\/p\u003e\n\u003cp\u003eThis model highlights Agenus's core value proposition of innovative cancer treatments, its distribution channels through clinical trials and potential commercialization, and its revenue streams from product sales and collaborations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAgenus's Business Model Canvas acts as a pain point reliever by visually mapping out their complex immunotherapy development, clarifying value propositions and customer segments for improved strategic focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscovery and Preclinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgenus's key activities in discovery and preclinical development center on identifying new targets for immuno-oncology and advancing antibody-based therapies, cancer vaccines, and cell therapies through early-stage research and testing. This rigorous process aims to pinpoint promising drug candidates for further development.\u003c\/p\u003e\n\u003cp\u003eThe company utilizes its proprietary platforms to construct a strong pipeline of potential treatments, a critical step in bringing innovative cancer therapies to market. For example, in 2024, Agenus continued to advance its preclinical programs, with a focus on optimizing lead candidates for IND-enabling studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Execution and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgenus's key activity centers on the meticulous design, execution, and oversight of multi-phase clinical trials for its innovative drug candidates, notably the combination of botensilimab and balstilimab (BOT\/BAL).\u003c\/p\u003e\n\u003cp\u003eThese trials are specifically designed to rigorously assess the safety and effectiveness of these novel therapies across a spectrum of challenging cancer indications, including microsatellite stable (MSS) colorectal cancer, pancreatic cancer, and gastroesophageal cancer.\u003c\/p\u003e\n\u003cp\u003eFor instance, Agenus reported in early 2024 that botensilimab and balstilimab demonstrated promising objective response rates in MSS colorectal cancer patients, with data from ongoing trials continuing to be pivotal for future regulatory submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgenus's key activities in regulatory affairs involve proactive engagement with agencies like the FDA to ensure clinical trial designs meet regulatory standards and to explore expedited approval pathways. This includes the meticulous preparation and submission of Biologics License Applications (BLAs) for their novel therapies.\u003c\/p\u003e\n\u003cp\u003eA significant focus is placed on the regulatory strategy for their BOT\/BAL program, aiming to streamline the path to market for these promising treatments. The company dedicates substantial resources to navigating complex regulatory requirements, a critical step in bringing innovative cancer immunotherapies to patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development and Partnering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAgenus actively pursues strategic alliances to advance its pipeline, focusing on co-development, manufacturing, and commercialization efforts. These partnerships are vital for broadening market reach and accessing specialized capabilities. For instance, in 2024, the company announced a collaboration leveraging AI for biomarker discovery, aiming to enhance clinical trial efficiency and patient selection.\u003c\/p\u003e\n\u003cp\u003eSecuring external funding and expertise through these collaborations is a cornerstone of Agenus's strategy. By teaming up with other entities, Agenus can de-risk development programs and accelerate the journey from research to market. Recent agreements highlight a commitment to building a robust network for both manufacturing and innovative research approaches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCo-development and Commercialization Partnerships:\u003c\/strong\u003e Agenus forms strategic alliances to share the costs and risks associated with drug development and to expand market access for its therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing Collaborations:\u003c\/strong\u003e The company engages in partnerships to secure reliable and scalable manufacturing capabilities, ensuring its product candidates can be produced efficiently.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI-Enabled Biomarker Discovery:\u003c\/strong\u003e A key focus in 2024 has been on leveraging artificial intelligence through partnerships to identify novel biomarkers, which can improve patient stratification and treatment outcomes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Footprint Expansion:\u003c\/strong\u003e Strategic partnering is instrumental in Agenus's efforts to extend its operational and commercial presence into new geographic regions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAgenus actively manages the manufacturing of its innovative biological drug candidates, a critical component of its business model. This involves a strategic focus on advancing its biologics Chemistry, Manufacturing, and Controls (CMC) capabilities to ensure the consistent production of high-quality therapies. \u003c\/p\u003e\n\u003cp\u003eThe company prioritizes maintaining robust production processes, whether through its internal facilities or by forging key external partnerships. This dual approach guarantees a reliable supply chain for both ongoing clinical trials and anticipated future commercial needs. \u003c\/p\u003e\n\u003cp\u003eA significant recent development underscoring this commitment to optimization is Agenus's strategic deal with Zydus Lifesciences. This collaboration is designed to enhance manufacturing efficiency and expand production capacity for its promising oncology pipeline, further solidifying its operational backbone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing Oversight:\u003c\/strong\u003e Agenus oversees the production of its biological drug candidates, including the development and scaling of its biologics CMC capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuality Assurance:\u003c\/strong\u003e Ensuring the high quality of therapies for clinical trials and commercial supply is paramount, achieved through internal expertise and strategic external collaborations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Partnerships:\u003c\/strong\u003e The company leverages partnerships, such as the recent agreement with Zydus Lifesciences, to optimize manufacturing processes and expand capacity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Development: Key Activities \u0026amp; 2024 Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgenus's key activities encompass the entire lifecycle of drug development, from initial discovery and preclinical research to robust clinical trial execution and regulatory navigation. This includes leveraging proprietary platforms to build a strong pipeline, with a notable focus in 2024 on advancing preclinical programs for IND-enabling studies and optimizing lead candidates. The company also actively manages manufacturing operations and strategic partnerships to ensure efficient production and broader market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2024 Focus\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscovery \u0026amp; Preclinical Development\u003c\/td\u003e\n\u003ctd\u003eIdentifying targets and advancing antibody-based therapies, cancer vaccines, and cell therapies.\u003c\/td\u003e\n\u003ctd\u003eOptimizing lead candidates for IND-enabling studies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eDesigning and executing multi-phase trials for novel drug candidates like BOT\/BAL.\u003c\/td\u003e\n\u003ctd\u003eDemonstrated promising objective response rates in MSS colorectal cancer patients with BOT\/BAL.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eEngaging with agencies and preparing submissions for expedited approval pathways.\u003c\/td\u003e\n\u003ctd\u003eStreamlining regulatory strategy for the BOT\/BAL program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Partnerships\u003c\/td\u003e\n\u003ctd\u003eForming alliances for co-development, manufacturing, and commercialization.\u003c\/td\u003e\n\u003ctd\u003eAnnounced collaboration leveraging AI for biomarker discovery.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eManaging production of biological drug candidates and advancing CMC capabilities.\u003c\/td\u003e\n\u003ctd\u003eStrategic deal with Zydus Lifesciences to enhance manufacturing efficiency.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Agenus Business Model Canvas preview you are viewing is the exact document you will receive upon purchase. This means you're seeing a direct representation of the final deliverable, ensuring no surprises in content or structure. Once your order is complete, you'll gain full access to this comprehensive Business Model Canvas, ready for your strategic planning and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611116257657,"sku":"agenusbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/agenusbio-business-model-canvas.png?v=1754751034","url":"https:\/\/growthsharematrix.com\/products\/agenusbio-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}